EMA Withdrawn: Staquis (Crisaborole) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA has withdrawn Staquis (crisaborole) from the market in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Staquis (crisaborole)

Snippet

Status: Withdrawn. Therapeutic area: Dermatitis, Atopic. MAH: Pfizer Europe MA EEIG. Decision date: 01/10/2021